关于中国医药行业市场预测的最权威报告IMS Market Prognosis China 2016-2020（IMS 中国医药行业市场研究分析报告）
报告是2016年9月份发布的，数据非常新。

Table of Contents
IMS Market Prognosis ........................................................................................................................... 1
Market Overview and Forecasts .......................................................................................................... 2
Market Synopsis............................................................................................................................ 2
Total Market Forecasts 2016-2020 ................................................................................................ 6
Analysis of Rebates and Discounts ..................................................................................... 6
Summary of the Prognosis .................................................................................................. 6
Hospital Sector Overview ............................................................................................................. 10
Hospital Sector Forecasts ................................................................................................. 11
Event Analysis............................................................................................................................. 13
Positive Events .................................................................................................................. 14
Negative Events ................................................................................................................ 17
Forecasting Data and Methods .................................................................................................... 22
Data Sources ..................................................................................................................... 22
Baseline Extrapolations ..................................................................................................... 23
Hospital Sector Baseline Extrapolations ........................................................................... 23
Economic Indicators .......................................................................................................... 24
Therapeutic Class Forecasts ....................................................................................................... 25
IMS Market Prognosis Report ............................................................................................................ 27
Business Environment ....................................................................................................................... 28
Economic Environment ................................................................................................................ 28
Economic Growth .............................................................................................................. 28
Inflation .............................................................................................................................. 28
Population .......................................................................................................................... 28
Fiscal Policy ....................................................................................................................... 29
Monetary Policy ................................................................................................................. 29
Foreign Trade and Current Account .................................................................................. 30
Exchange Rates ................................................................................................................ 30
Political Environment ................................................................................................................... 32
Political Institutions ............................................................................................................ 32
Current Government .......................................................................................................... 32
Policy Trends ..................................................................................................................... 33
International Relations ....................................................................................................... 34
Healthcare Environment ..................................................................................................................... 35
Healthcare Provision .................................................................................................................... 35
Healthcare System ............................................................................................................ 35
Health Status ..................................................................................................................... 37
Healthcare Policy ............................................................................................................... 40
Healthcare Financing and Expenditure ............................................................................. 42
Pharmaceutical Expenditure .............................................................................................. 43
Health Insurance ............................................................................................................... 44
Market Prognosis 2016-2020 | China
iv
Hospital Sector .................................................................................................................. 49
Primary Care...................................................................................................................... 54
Drug Procurement ............................................................................................................. 55
E-Health ............................................................................................................................. 60
Prescribing and Dispensing ......................................................................................................... 62
Prescribing Influences ....................................................................................................... 62
Essential Drug List ............................................................................................................. 66
National Reimbursement Drug List.................................................................................... 68
Hospital Formularies .......................................................................................................... 71
Dispensing ......................................................................................................................... 71
Pricing ......................................................................................................................................... 74
Pricing System ................................................................................................................... 74
National-Level Price Negotiations ..................................................................................... 76
Reimbursement Standards ................................................................................................ 78
Price Trends ...................................................................................................................... 80
Health Technology Assessment ........................................................................................ 80
Discounts and Margins ...................................................................................................... 81
Regulatory Environment .............................................................................................................. 82
Drug Registration ............................................................................................................... 82
Drug Administration Law ................................................................................................... 86
Biosimilars ......................................................................................................................... 87
Clinical Trials ..................................................................................................................... 88
Quality Standards and Drug Safety ................................................................................... 89
Marketing and Promotion .................................................................................................. 93
Intellectual Property ........................................................................................................... 93
Pharmaceutical Business Environment ....................................................................................... 95
Operating Environment ...................................................................................................... 95
Industry Structure .............................................................................................................. 96
Leading Corporations ........................................................................................................ 98
Leading Products ............................................................................................................... 99
Research and Development ............................................................................................ 100
Generics .......................................................................................................................... 102
Distribution ....................................................................................................................... 103
Retail Pharmacy .............................................................................................................. 105
OTC Market ..................................................................................................................... 107
Sales and Marketing ........................................................................................................ 108
Appendix A: Glossary ....................................................................................................................... 110
Appendix B: Sources and Methods ................................................................................................ 112